Inhalation Therapy in Patients Receiving Mechanical Ventilation: An Update by Ari, Arzu et al.
Georgia State University
ScholarWorks @ Georgia State University
Respiratory Therapy Faculty Publications Department of Respiratory Therapy
11-28-2012
Inhalation Therapy in Patients Receiving
Mechanical Ventilation: An Update
Arzu Ari
Georgia State University, aari1@gsu.edu
James B. Fink
Georgia State University, jfink@gsu.edu
Rajiv Dhand
University of Tenn, rdhand@uthsc.edu
Follow this and additional works at: https://scholarworks.gsu.edu/rt_facpub
Part of the Respiratory System Commons
This Article is brought to you for free and open access by the Department of Respiratory Therapy at ScholarWorks @ Georgia State University. It has
been accepted for inclusion in Respiratory Therapy Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University.
For more information, please contact scholarworks@gsu.edu.
Recommended Citation
Arzu Ari, James B. Fink, and Rajiv Dhand. Journal of Aerosol Medicine and Pulmonary Drug Delivery. December 2012, 25(6):
319-332. doi:10.1089/jamp.2011.0936.
Inhalation Therapy in Patients Receiving Mechanical
Ventilation: An Update
Arzu Ari, Ph.D., R.R.T., FAARC,1 James B. Fink, Ph.D., R.R.T., FAARC,1
and Rajiv Dhand, M.D., FACP, FCCP, FAARC2
Abstract
Incremental gains in understanding the influence of various factors on aerosol delivery in concert with tech-
nological advancements over the past 2 decades have fueled an ever burgeoning literature on aerosol therapy
during mechanical ventilation. In-line use of pressurized metered-dose inhalers (pMDIs) and nebulizers is
influenced by a host of factors, some of which are unique to ventilator-supported patients. This article reviews
the impact of various factors on aerosol delivery with pMDIs and nebulizers, and elucidates the correlation
between in-vitro estimates and in-vivo measurement of aerosol deposition in the lung. Aerosolized bronchodi-
lator therapy with pMDIs and nebulizers is commonly employed in intensive care units (ICUs), and broncho-
dilators are among the most frequently used therapies in mechanically ventilated patients. The use of inhaled
bronchodilators is not restricted to mechanically ventilated patients with chronic obstructive pulmonary disease
(COPD) and asthma, as they are routinely employed in other ventilator-dependent patients without confirmed
airflow obstruction. The efficacy and safety of bronchodilator therapy has generated a great deal of interest in
employing other inhaled therapies, such as surfactant, antibiotics, prostacyclins, diuretics, anticoagulants and
mucoactive agents, among others, in attempts to improve outcomes in critically ill ICU patients receiving
mechanical ventilation.
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Introduction
In the 1980s, there was a widely prevalent opinion thataerosolized therapies were unlikely to be successful in
mechanically ventilated patients because of the extremely
poor efficiency of drug delivery in this setting.(1) Many bar-
riers, especially the inability of drug particles to negotiate the
ventilator circuit and endotracheal tube, were thought to
preclude effective aerosol delivery to ventilator-supported
patients, and this view was supported by landmark studies
that corroborated the low pulmonary deposition of aerosol-
ized drugs in this patient population compared to ambula-
tory, nonintubated patients.(2) In the past, the poor efficiency
of aerosol-generating devices in ventilator circuits, inade-
quate understanding of the factors influencing aerosol deliv-
ery during mechanical ventilation, and older generation
mechanical ventilators that were not designed for aerosol use
posed major impediments to effective drug delivery. The
successful transformation to a higher efficiency of aerosol
delivery is due to the efforts of several investigators who have
collectively helped to clarify the optimal techniques for in-
halation therapy during mechanical ventilation. This article
updates the literature on inhalation therapy and discusses the
appropriate methods to employ for administration of inhaled
drugs in adult ventilator-supported patients.
Adequate amounts of the drug need to deposit in the lung
to produce clinical effects.(3) The amount of drug delivered to
the lower respiratory tract can be predicted on the basis of
bench models of mechanical ventilation that simulate the
clinical setting.(4) With pressurized metered-dose inhalers
(pMDIs), the drug output per actuation is already defined,
and several elegantly performed in vitro studies permit fairly
precise prediction of drug deposition in the lung.(5,6) The
amount of drug delivered to the lung with a nebulizer can
also be estimated under specified conditions of nebulizer
operation so that the time required to deliver a known
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amount of drug can be accurately estimated.(7) Therefore, the
ability to control circuit conditions, ventilatory parameters,
and conditions of nebulization allows estimation of drug
delivery with a range of nebulizers that differ in their oper-
ational efficiency. In addition to the total amount of drug
delivered, the precision, reliability, and consistency of dosing
are important factors that influence the response to treat-
ment.(3,4) Adequate understanding of the factors governing
lung deposition of aerosols is essential to achieve these goals.
The complexity of aerosol therapy in ventilator-dependent
patients is due to the interaction of a host of factors that
determine drug deposition in the lung. During the past 2
decades, impressive gains in knowledge about the interplay
of these factors, for example, humidity, duty cycle, and de-
vice configuration and placement in the circuit, have con-
tributed immensely to improved methods for aerosol
delivery.(8) Newer designs of nebulizers that employ a vi-
brating plate with multiple apertures to generate aerosol(9)
and hydrofluoroalkane (HFA)-propelled pMDIs(10,11) also
significantly influence delivery of aerosols during mechani-
cal ventilation. The purpose of this article is to review the
scientific principles underlying the use of inhaled therapies
in adult mechanically ventilated patients, with an emphasis
on recently published literature.
Factors Influencing Aerosol Delivery During Mechanical
Ventilation: Lessons From the Bench
pMDIs
Over the past 25 years, the pMDI has been accepted as a
cost effective, convenient, reliable, and safe aerosol generator
for use with mechanically ventilated patients.(12) As pMDIs
were never designed or intended for delivery of inhaled
medications to mechanically ventilated patients, their adap-
tation for efficient aerosol delivery in this setting involved
substantial innovation and experimentation. For pMDIs to be
employed in ventilator-supported patients, third-party ac-
tuator devices that could be connected in closed, pressurized
circuits were required. These devices range from simple
adapters with a port and single nozzle to more complex
spacer chambers.(13–16) The performance of these devices
varies between adapter designs, and within the same adapter
type between pMDI formulations, including both the drug
and the propellants used. In vitro studies have shown that
aerosol drug delivery to the lower respiratory tract ranges
from 0.3 to 97.5% with pMDIs.(2,5,6,17–21) This level of vari-
ability in drug delivery can spell the difference between ef-
fective and unsuccessful therapy.
Most of the data regarding the relative attributes of these
devices is based on reported in vitro testing by individual
investigators. Multiple factors influencing the efficiency of
aerosol delivery with pMDIs are discussed below:
1. Timing of actuation: The timing of pMDI actuation in
relation to the ventilator airflow has a marked influence
on delivered dose of medication. According to Diot
et al.,(20) failure to synchronize actuations with inspi-
ration reduced inhaled mass by 35%. Likewise, Alzah-
rani and colleagues(22) reported that actuations of a
pMDI repeated every 15 s independent of the breathing
pattern resulted in a lower inhaled mass (3.7 – 1.3% of
the emitted dose) compared to actuations synchronized
with the start of inspiration, and with more than a 15-s
interval between successive actuations (14.47 – 2.5%).
By using a model of noninvasive ventilation, Brancon-
nier and Hess(23) reported that actuation at the onset of
inspiration resulted in at least 40% higher inhaled dose
than actuation during expiration. Actuation of a pMDI
must be synchronized with the precise onset of inspi-
ration to maximize aerosol drug delivery.
2. Priming and shaking the canister: All manufacturers rec-
ommend shaking and priming the pMDI with several
actuations to the atmosphere prior to first use, and after
specified periods of time between uses.(24) With the
transition from chlorofluorocarbon (CFC) to HFA pro-
pellants, recommended periods between priming have
been extended up to several days. However, the failure
to shake a pMDI canister that has been standing over-
night may decrease total emitted and respirable dose by
as much 25 and 35%, respectively, because the drugs in
pMDI formulations tend to separate from their pro-
pellants during this interval.(25) Therefore, it is good
practice to prime a pMDI before first use and if it has
not been actuated for more than 24 h. pMDIs should be
shaken before the first actuation of each dose (series of
actuations) administered. However, once shaken, up to
eight actuations from a pMDI can be sequentially ad-
ministered within a short time period without a re-
duction in emitted dose.(5) Similarly, during mechanical
ventilation pMDI actuation at 15-s intervals resulted in
emitted doses that were comparable to those obtained
by actuation after the 1- min interval recommended on
the device label.(5)
3. Actuator designs: Several actuators with different de-
signs and sizes are available on the market for aerosol
drug delivery in mechanically ventilated patients. Rau
et al.(18) tested the efficiency of three different setups: an
elbow adapter at the endotracheal tube (ETT); an in-line
spacer chamber (Aerovent, Monaghan Medical, Platts-
burgh, NY) placed in the inspiratory limb just before the
Y adapter; and an in-line chamber placed between the Y
and endotracheal tube. A total of 10 actuations were
administered at 30-s intervals in a dry circuit. The pMDI
with elbow adapter delivered the least (7.3%), whereas
the chamber delivered 32.1% when placed in the in-
spiratory limb, and 29% deposition when placed at the
ETT.
Subsequent studies confirmed that the use of a
chamber shaped spacer with the pMDI results in four-
to sixfold greater aerosol drug delivery when compared
with either an elbow adapter or a unidirectional in-line
spacer.(18,26,27) In contrast, the efficiency of a bidirec-
tional in-line spacer was higher than the efficiency of a
unidirectional in-line spacer and it achieved comparable
efficiency with chamber spacers.(28)
4. Placement of the pMDI in the ventilator circuit: Placing the
spacer chamber in the inspiratory limb of the ventilator
circuit, 15 cm from the ETT increases aerosol deposition
with improved potential for clinical response.(23,29) Ari
and colleagues,(17) using a heated/humidified in vitro
model of adult ventilation quantified the percent of
emitted dose delivered distal to an endotracheal tube
from an albuterol HFA-pMDI with chamber adapter, in
each of three positions: between ETT and Y-piece
2 ARI ET AL.
(7.6 – 1.3%), in the inspiratory limb 15 cm from Y-piece
(17.0 – 1.0%), and 15 cm from the ventilator before the
inlet of the humidifier (2.5 – 0.8%). The deposition effi-
ciency achieved with placement of the pMDI and
chamber adapter 15 cm from the Y piece (17% of the
emitted dose) was similar to that achieved using ul-
trasonic and vibrating mesh nebulizers in the same
position.
5. Heat and humidity: Bench models of mechanical venti-
lation clearly established that aerosol drug delivery is
reduced by up to 40% in heated/humidified ventilator
circuits compared to nonhumidified unheated cir-
cuits.(5,6,20,30–32) Although higher deposition with de-
livery of cold dry gas might seem attractive as a means
to deliver more drug to the lung, the increased effi-
ciency of aerosol delivery must be weighed against the
potential deleterious effects of prolonged ventilation
with cold dry gases.(32) Active heated humidifiers are
commonly used during mechanical ventilation of in-
fants and small children, and a substantial proportion
of adults. The heat and humidity of an inhaled gas to
body temperature pressure saturated (BTPS) conditions
promotes mucociliary clearance, prevents drying of the
airway mucosa, and reduces bronchospastic responses
to breathing cold dry air. The reduction in aerosol de-
livery with heated humidity in the ventilator circuit has
been associated with changes in aerosol particle size
during mechanical ventilation.(5,6,20,30–32) However,
Lange and Finlay(33) demonstrated that the decrease in
inhaled drug mass was directly related to the mole
fraction of water vapor in the inspired air, rather than to
the relative humidity or the temperature of the inhaled
gas. These investigators demonstrated that hygroscopic
growth was not responsible for the excessive drug los-
ses in the spacer and ETT, and they hypothesized that
an interaction between the water molecules in the air
and the surfactant present in the propellant/drug sus-
pension may have caused a reduction in the evapora-
tion rate of propellant.(33) In addition, they also
reported that drug delivery in a ventilator circuit with a
correctly dimensioned spacer could be even more effi-
cient than under ambient conditions in spontaneously
breathing patients.(33)
Despite the unwanted effects of humidity on drug
delivery, removing the humidifier is not recommended
for routine aerosol therapy as it requires breaking the
circuit and waiting several minutes for the circuit to
dry.(34) Moreover, the effects of turning off the heated
humidifier on aerosol delivery are difficult to predict.
For example, efficiency of albuterol delivery from a
pMDI with spacer chamber during mechanical venti-
lation with a heated wire circuit was not reduced for
more than 1 h after turning on the heated humidifier.(35)
Aerosol delivery was decreased when substantial con-
densation was noted in the spacer and tubing, with
reductions to levels previously reported with humidi-
fied ventilator circuits. After 3 h of humidifier opera-
tion, turning off the humidifier for up to 30min prior to
administration of aerosol via pMDI did not improve
drug delivery.(35) As suggested by the authors,(35) the
presence of water condensate probably achieved a high
enough absolute humidity in the circuit and chamber
that continued to reduce delivery efficiency of the in-
haled aerosol for some time interval after turning off the
humidifier.
For inexpensive drugs, such as salbutamol or ipra-
tropium bromide, increasing the administered dose of
drug may be safer than turning off the humidifier. For
more expensive drugs, such as antibiotics, the potential
efficiency advantage of a dry ventilator circuit may be
cost-effective; however, this has yet to be demonstrated
in vivo. If a dry ventilator circuit needs to be used for
aerosol delivery, a heat moisture exchanger (HME)
should be employed, and the medication administered
within a short period (less than 10min) to minimize the
dehydrating effects on the airway mucosa.(36)
Heat and moisture exchangers (HMEs) capture the
heat and moisture in the exhaled air and transfer part of
the heat and humidity to the next inspired breath, pro-
viding about 70% absolute humidity at 30C. The filter
in the HME, presents a formidable barrier to aerosol
delivery, and it must never be placed between the
aerosol-generating device and the patient during aerosol
administration. In addition, during nebulization for ex-
tended periods the nebulizer output has the potential to
overload the HME filter with both drug and liquid, and
increase the work of breathing through the device.
6. Density of inhaled gas: High inspiratory flow during
mechanical ventilation produces transitional and tur-
bulent flows in the narrow airway passages that causes
aerosol to impact on the ventilator circuit and in the
artificial airway.(37) Inhaling a helium–oxygen mixture
allows laminar flows to persist in the airways, and may
improve aerosol deposition by decreasing impaction
losses caused by airflow turbulence.(38) In a bench
model of mechanical ventilation, Goode and col-
leagues(39) reported that a 80/20 helium/oxygen (He-
liox) mixture increased aerosol deposition from pMDIs
and nebulizers up to 50% when compared to using
oxygen alone. Aerosol delivery efficiency and gas den-
sity in the ventilator circuit are inversely related. The
lowest gas density (80/20 helium/oxygen) provides the
highest bronchodilator delivery but it also reduces
aerosol generation with a jet nebulizer.(39)
Because of its lower density, heliox is not as effective in
aerosolizing liquid medications via jet nebulization, and it
should not be used to power the nebulizer.(39,40) When a
helium/oxygen mixture is employed, flow to the nebulizer
must be increased by twofold or more than flows of air or
oxygen in order to achieve a comparable aerosol output.(39,41)
A preferred strategy in maximizing aerosol deposition with a
nebulizer is to power it with 6 to 8 L/min of oxygen and
entrain the aerosol into a ventilator circuit that contains he-
liox.(39,40) Tassaux et al.(42) showed that aerosol deposition to
the lower airways is increased by 50% with that method
compared to using oxygen alone in the ventilator circuit.
Heliox may adversely affect the function of some ventilators,
so the ventilator must be tested with heliox to detect any
malfunction before use in patients.(42)
As a practical consideration, the available drug op-
tions available in pMDIs are limited. Relative cost effec-
tiveness of the pMDI has shifted as the costs of HFA-pMDIs
have risen, sometimes dramatically, over their CFC-propelled
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predecessors. For example, each dose of four puffs of albu-
terol from a HFA-pMDI ($140 for 200 puffs) would cost
$2.80, compared to a unit dose of the liquid formulation that
costs less than $1.
In summary, pMDIs offer a safe and effective method for
administration of medications to the lungs of patients re-
quiring mechanical ventilator support. If the prescribed
drugs are available in this dosage form, and a standard dose
provides the desired clinical response, then the pMDI is an
excellent option. Careful attention to the details of adminis-
tration, such as the timing of actuation, actuators used, and
placement of the device in the ventilator circuit, are required
to optimize therapy.
Nebulizers
Three principal designs of nebulizers, namely jet nebuliz-
ers, ultrasonic nebulizers and mesh nebulizers, are employed
to deliver liquid formulations of medications such as bron-
chodilators, antibiotics, corticosteroids, surfactant, mucolytic
agents, anticoagulants, and prostanoids to mechanically
ventilated patients (Table 1).
Jet Nebulizers. For the past several decades, jet nebu-
lizers have been commonly employed for aerosol delivery
during mechanical ventilation because they are readily
available in most hospitals, easy to use, and relatively inex-
pensive compared with vibrating mesh and ultrasonic neb-
ulizers. However, entrainment of an additional 2–10 L/min
of gas into the ventilator circuit during nebulizer operation
could influence tidal volumes and pressures delivered to the
patient. Also, jet nebulizers may inactivate or denature the
drug due to shear forces generated during the process of
nebulization.(43–45) The medication reservoir also serves as
the nebulization chamber. As larger particles are produced,
they return to the medication reservoir and the medication is
renebulized, resulting in evaporative effects associated with
increasing concentration of medication over time. In addi-
tion, residual drug volumes remaining in the reservoir at the
end of nebulization range from 0.8–1.4mL with various jet
nebulizers. Such operational inefficiencies of jet nebulizers
make them less than ideal for many patients receiving me-
chanical ventilation.
Ultrasonic nebulizers. Although several brands of ultra-
sonic nebulizers are available, they are not commonly em-
ployed during mechanical ventilation due to their bulkiness,
high cost, production of aerosols with larger particle size
than jet nebulizers, relative inefficiency to aerosolize viscous
solutions or suspensions, and degradation of heat-sensitive
materials.(46–48) Typical residual volumes of drug remaining at
end of nebulization in various ultrasonic nebulizer brands
range from 0.5–1.0mL.
Vibrating mesh nebulizers. The vibrating mesh nebuliz-
ers are associated with higher efficiency than jet or ultrasonic
nebulizers, due in part to the lower residual volume (ranging
from 0.1–0.5mL).(13) Unlike other nebulizers (jet or ultra-
sonic), the medication reservoir in vibrating mesh nebulizers
is separated from the ventilator circuit and lies above the
mesh and the ventilator circuit. Because of this orientation,
the risk of contaminated condensate entering the medication
reservoir is reduced. Because vibrating mesh nebulizers
generally produce aerosols with a higher respirable fraction,
the nominal dose of drugs to be administered for clinical
effects could be reduced compared to jet nebulizers.(9,43)
Other advantages of the vibrating mesh nebulizers are that
they can be battery operated, and thus are more portable and
less noisy than jet nebulizers. Because vibrating mesh neb-
ulizers neither cool nor heat the solution, there is minimal
risk of denaturation and they could be safely employed to
aerosolize complex microstructures and large molecules.(49)
For instance, Perera et al.(50) showed that repeated adminis-
tration of inhaled insulin results in comparable dosing re-
producibility and shorter time to maximal metabolic effect
compared with subcutaneously administered insulin. They
found that the delivery of inhaled insulin through a mesh
nebulizer is well tolerated by patients and concluded that the
delivery system for delivering inhaled insulin is clinically
applicable.
Many factors influence nebulizer efficiency during me-
chanical ventilation, including the type of nebulizer, residual
volume, mode of nebulization, position of nebulizer in the
ventilator circuit, gas flow, and bias flow.(32) Such factors
influence the emitted dose and make it harder to provide
objective comparisons of clinical outcomes. Although aerosol
delivery during mechanical ventilation has been studied
extensively in vitro, testing of nebulizers has been much less
rigorous in vivo.
1. Type of nebulizer: Both the type of nebulizer and differ-
ent batches of the same nebulizer brand show vari-
ability in aerosol output.(17,51–53) Jet nebulizers are less
efficient than ultrasonic and vibrating mesh nebuliz-
ers,(9,13,17,53–55) because the latter provide a higher rate
of nebulization in a shorter period of time.(9,17,34,53,56)
Alvine et al.(51) evaluated the nebulization rate and
particle size of eight disposable jet nebulizers and found
considerable variability of nebulization rate within
specific models.(51) Loffert et al.(57) tested 17 commer-
cially available jet nebulizers by filling them with 2mL
Table 1. Inhaled Medications Employed During
Mechanical Ventilation
Bronchodilator
Beta-agonist (albuterol, terbutaline, metaproteronol,
fenoterol)
Anticholinergic (ipratropium bromide)
Combination beta-agonist and anticholinergic
(albuterol sulfate + ipratropium bromide)
Combination long-acting beta-agonist and inhaled
corticosteroid (salmeterol +fluticasone;
formoterol +budesonide)
Prostaglandins
Mucoactive agents
Dornase alpha
Surfactant
Antibiotics
Antibacterial
Antiviral
Antifungal
Corticosteroids (beclomethasone; budesonide, fluticasone)
Anticoagulants (Heparin)
Miscellaneous
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of saline solution and 0.5mL of albuterol. They found
that the output characteristics of commercial nebulizers
vary greatly in terms of nebulization time and the total
amount of drug delivered to the lungs.(57) Therefore, the
efficiency of a nebulizer must be characterized before
using it for drug delivery to mechanically ventilated
patients.
2. Residual (dead) volume: Residual volume, that is, the
amount of medication remaining in the nebulizer at the
end of a treatment, can range from 0.1 to 2.4mL de-
pending on the type of nebulizer. Jet nebulizers have a
higher residual volume, nebulize less of a proportion of
the drug, and do not function well with fill volumes
below 2mL.(13) Therefore with jet nebulizers, it is re-
commended to use a fill volume of 4–5mL unless the
nebulizer is specifically designed for a smaller fill vol-
ume.(52) Vibrating mesh nebulizers have smaller resid-
ual volumes than jet and ultrasonic nebulizers.(13,45,58)
Compared to jet nebulizers, the higher costs of ultra-
sonic and mesh nebulizers has limited their utilization
in ventilated patients.
3. Nebulizer position in the ventilator circuit: Placement of a
jet nebulizer farther away from the endotracheal tube
improves aerosol delivery(17,30,53,59–61) because the
ventilator tubing acts as a spacer in which the aerosol
accumulates between breaths. The continuous output of
gas from the jet nebulizer charges the inspiratory limb
of the circuit between inspirations, increasing the pro-
portion of drug output delivered with each ventilator
breath. This explanation was confirmed by Ari et al.,(17)
who reported that during conventional ventilation with
no bias flow, placement of a pMDI, ultrasonic nebulizer,
or vibrating mesh nebulizer proximal to the ventilator
reduced delivery compared to standard placement
proximal to the patient. Although it may seem coun-
terintuitive to place an aerosol generator before the inlet
of the humidifier, these investigators noted that in the
presence of bias flow, delivery efficiency of the vibrat-
ing mesh nebulizer was greater when it was placed in
proximity with the ventilator (Fig. 1). The clinical rele-
vance of this observation is unclear, because in a clinical
study Moraine et al.(62) reported that the placement of a
vibrating mesh nebulizer in close proximity to the
ventilator, that is, before the humidifier, did not affect
the urinary excretion of ipratropium bromide compared
to placement in the inspiratory limb near the circuit Y.
4. Bias flow (trigger flow): Ari et al.(53) studied the influence
of bias flow with a jet and vibrating mesh nebulizer on
albuterol sulfate delivery in a model of adult mechan-
ical ventilation. They reported that increasing bias flows
through the ventilator circuit decreased the amount of
aerosol deposited. During continuous nebulization,
FIG. 1. Key components of an in vitro setup to quantify delivery of aerosol drug distal to the endotracheal tube during
mechanical ventilation, with placement of a jet nebulizer (A) and vibrating mesh nebulizer (B) in the inspiratory limb
proximal to the patient (position 1) and proximal to the ventilator (position 2). (Reproduced with permission, from Ari
et al.(53))
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they recommended that aerosol delivery could be en-
hanced by reducing bias flow to £ 2 L/min.(53)
5. Mode of nebulization. Pressurized gas from a 50 psi wall
outlet or gas cylinder is commonly employed to operate
nebulizers continuously. Alternatively, nebulizers may
be operated by driving pressure and gas flow from the
ventilator, and this intermittent operation allows the
ventilator to maintain a constant tidal volume and
minute ventilation by compensating for the nebulizer
flow. Intermittent nebulizer operation synchronized
with inspiratory airflow from the ventilator minimizes
aerosol losses during exhalation, and has a 35 to 400%
higher efficiency for drug delivery than continuous
nebulization.(60,63) However, the lower driving gas
pressure provided by some ventilators may influence
the efficiency and quality of nebulizer output. The ef-
ficiency of breath actuation may also be influenced by
the time gap between initiation of powering the nebu-
lizer and aerosol generation. This time gap may be up
to 80ms with jet nebulizers and > 150ms with ultra-
sonic nebulizers. Built-in nebulizer functionality in
some newer generation ventilators takes into account
changes with nebulizer operation, and facilitates more
reproducible and consistent dosing.(36,64,65)
6. Gas flow. Each model of jet nebulizers is designed to
work best at a specific flow, ranging from 2–10 L/min,
which should be listed on the device label. Operating
any jet nebulizer at a lower flow or pressure increases
aerosol particle size, and thereby reduces pulmonary
drug delivery. Moreover, reducing the gas flow pro-
duces a proportionate increase in nebulization time. In
contrast to jet nebulizers, ultrasonic and vibrating mesh
nebulizers are operated by electricity and they are not
influenced by gas flow.
In summary, nebulizer operation during mechanical ven-
tilation could have widely variable efficiency for aerosol
delivery unless careful attention is given to a number of
factors that influence nebulizer performance.
Soft-mist inhaler
A new adapter has been designed for in-line use of the
Respimat soft mist inhaler (Boehringer-Ingelheim, Ger-
many). The in vitro dose delivery of tiotropium, and ipra-
tropium bromide and albuterol in combination, was
compared with pMDI delivery using different valved hold-
ing chambers and spacers during simulated mechanical
ventilation. The Respimat with the prototype in-line adapter
provided better fine particle dose delivery than other acces-
sory device combinations.(66)
Assessment of Aerosol Deposition in Mechanically
Ventilated Patients
Several investigators have used radionuclides and mea-
sured plasma or urinary drug levels to determine pulmonary
deposition of aerosols in ventilated patients.
Radionuclide studies
In ventilated patients, the pulmonary deposition of neb-
ulized radiolabeled aerosol has varied by more than 25-fold
(*1 to *30% of the nominal dose).(2,21,59,67) Several factors,
including type of radiolabel used, nebulizer brand, treatment
time, circuit humidity, and methods used to calculate the
amount of aerosol deposition,(30,63,67) contribute to the re-
ported variation. With a pMDI and spacer chamber, about
6% of the dose was deposited in the lower respiratory
tract,(21,27) and this value was significantly lower than pre-
viously reported values (10–20%) with a pMDI and spacer in
nonintubated ambulatory patients.(68,69)
Pharmacokinetic studies
Estimation of plasma levels of drugs administered by a
pMDI/nebulizer reflects lower respiratory tract deposition in
ventilated patients because the endotracheal tube prevents
oropharyngeal deposition and subsequent enteral absorption
during inspiration. There is the potential for exhaled drug to
bypass the ETT cuff and deposit in the oropharynx, but this
amount is generally minimal and should not make a signif-
icant contribution to the plasma levels. After administration
of albuterol with a pMDI and spacer, the area under the
concentration–time curve was only marginally lower in
ventilated patients than in healthy controls.(70) Moreover,
measurement of urinary albuterol excretion in 30 ventilated
patients with normal renal function showed that albuterol
recovery was highest (38% of the nominal dose) after ad-
ministration with a pMDI and chamber spacer, intermediate
with a nebulizer (16%), and lowest (9%) with a pMDI and
right angle port connected to the endotracheal tube.(71) With
an optimal technique of administration, pulmonary drug
deposition in ventilated patients is comparable to that
achieved in healthy controls. Measurement of urinary drug
excretion has also been employed to compare the efficiency
of drug delivery during mechanical ventilation. Moraine
et al.(62) measured urinary ipratropium levels after ultrasonic
nebulization in ventilated patients, and found no differences
in urinary ipratropium levels with the nebulizer placed close
to the circuit Y or when it was placed before the heated
humidifier. In ventilated patients, pharmacokinetic studies
could be a useful adjunct to in vitro studies for comparing
device efficiency, and to establish optimal techniques of ad-
ministration with specific devices.
In vitro/In vivo correlation
In vitro tests play an important role in elucidating the
contribution of each of a complex array of factors influencing
drug delivery.(5–8) The wide discrepancy between in vitro and
in vivo estimates of aerosol delivery has been reconciled by
comparing data from bench models with in vivo scinti-
graphic studies.(6)
In vitro models commonly use an absolute filter to collect
drug distal to the artificial airway. This is likely to overesti-
mate in vivo deposition, because the filter deposition mea-
sures inhaled mass, and some of this inhaled aerosol does
not deposit in the lung and is exhaled. Thus, the filter de-
position does not account for the proportion of drug that is
exhaled by the patient.(6,72) When the difference between
drug exhaled in vitro and in vivo is subtracted from the
in vitro drug deposited distal to the ETT, the calculated dose
is comparable to pulmonary deposition of radiolabeled
aerosol in mechanically ventilated patients after adjusting for
tissue absorption of radioactivity.(6,27)
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Bronchodilator Therapy
Bronchodilators are among the most commonly used
drugs in the intensive care unit (ICU),(73) but many other
inhaled medications are also employed during mechanical
ventilation (Table 1). Table 2 shows the indications for using
bronchodilator therapy in ventilator-supported patients. The
goals of bronchodilator therapy are to reverse bronchocon-
striction, decrease the work of breathing, and/or relieve
dyspnea. Administration of either aerosolized b-adrener-
gic(26,29,74–93) or anticholinergic drugs(77,79,83,86) produces
significant bronchodilator responses in ventilated patients.
The combination of fenoterol and ipratropium bromide was
found more effective than ipratropium alone in ventilated
patients with COPD.(94)
Combinations of inhaled corticosteroids (ICS) plus long-
acting b-agonist (LABA) (Advair, GSK, Research Triangle
Park, NC; Symbicort Astra Zeneca, Wilmington, DE) are
among the most effective and widely used treatments cur-
rently available for treatment of asthma. A combination of
formoterol and budesonide used as a reliever as well as
maintenance therapy may be employed for treatment of mild
to moderate acute asthma exacerbations that could be man-
aged at home. This management strategy significantly re-
duces the frequency of more severe exacerbations.(95)
Currently, there is limited experience with bronchodilator
and ICS combination therapy for treatment of acute exacer-
bations of chronic obstructive pulmonary disease (COPD),
especially in ventilated patients.
In patients receiving long-term ventilation for severe
COPD, Nava and colleagues(96) observed a small but statis-
tically significant reduction in airway resistance with inhaled
fluticasone. The optimal methods of administering ICS and
the appropriate doses in ventilated patients have not been
determined, but, based on the experience with asthma and
COPD patients in the Emergency Department, they are likely
to be higher than those used for maintenance therapy for
these disorders.(97–100) Significant costs could accrue from
inhaled therapy with a ICS and LABA combination, espe-
cially if higher doses are needed. Furthermore, many venti-
lated patients receive systemic corticosteroids for acute
exacerbations of asthma and COPD, and it is unclear if pa-
tients derive additional benefits from ICS in the presence of
high-dose therapy with oral or parenteral corticosteroids.
Finally, regular use of ICS in ambulatory patients with
COPD is associated with a higher risk of pneumonia.(101)
Because ventilated patients are already vulnerable to devel-
oping pneumonia for a variety of reasons, the potential to
add another risk factor by administering ICS requires serious
consideration. In summary, ICS may have a limited role in
ventilated patients, but further investigations are needed to
determine the appropriate dosing regimen and risk–benefit
of using ICS or ICS and LABA in this group of patients.
Bronchodilator efficacy
Most mechanically ventilated patients with COPD dem-
onstrate an improvement in respiratory mechanics following
bronchodilator administration with a pMDI or a nebu-
lizer (Table 3).(26,88) Application of external positive end-
expiratory pressure (PEEP) at a level that counterbalanced
intrinsic PEEP enhanced the bronchodilator effect of albu-
terol in mechanically ventilated patients with COPD.(91) In
contrast, Guerin and colleagues(102) reported that after
administration of nebulized fenoterol respiratory mechanics
improved when PEEP was set a zero. Increasing the set PEEP
to 85% of the intrinsic PEEP level did not enhance the
bronchodilator response. The use of a spacer with a pMDI
also improves the efficacy of bronchodilator therapy in
ventilator-supported patients. The best results are obtained
when the pMDI actuation is synchronized with the onset of
inspiration.(3,8) With careful attention to the technique of
administration, a bronchodilator response can be expected in
most mechanically ventilated patients with asthma or COPD.
In mechanically ventilated patients, significant broncho-
dilator effects occur after administration of 2.5mg of albu-
terol with a standard nebulizer,(82,88) or four puffs (400 lg)
with a pMDI (Fig. 2) (Table 3 ).(103) Minimal therapeutic
advantage was gained by administering higher doses,
whereas the potential for side effects was increased.(82,103) In
certain clinical settings, higher doses of bronchodilators may
be needed in patients with severe airway obstruction or if the
technique of administration is not optimal. With a carefully
executed technique of administration (Tables 4 and 5), most
stable mechanically ventilated patients with COPD achieve
near maximal bronchodilation following administration of
four puffs of albuterol with a pMDI or 2.5mg with a nebu-
lizer (Fig. 2).(40)
The duration of bronchodilator response in stable me-
chanically ventilated patients with COPD appears to be
shorter than that in ambulatory patients (2–3 h vs. 4–6 h,
respectively) and subject to considerable interpatient vari-
ability.(88,90) Thus, ventilated patients should receive sched-
uled administration of short-acting b-agonist bronchodilator
(albuterol) every 3 to 4 h.
In addition to patients with confirmed expiratory airflow
obstruction due to asthma or COPD, expiratory flow was
also shown to improve after bronchodilator administration
in a heterogeneous group of ventilated patients.(76) Neb-
ulized metaproterenol reduced elevated levels of airway re-
sistance in patients with acute respiratory distress syndrome
(ARDS).(104,105) b-Agonists could also enhance clearance of
fluid from the alveoli and accelerate the resolution of alve-
olar edema in patients with acute lung injury or acute re-
spiratory distress syndrome (ARDS). However, a recently
concluded multicenter trial by the ARDS Network found that
administration of nebulized albuterol (5mg every 4 h for up
to 10 days) did not improve ventilator-free days, or mortality
at 60 days or 90 days after enrolment.(106) Although bron-
chodilators are currently administered to a wide spectrum of
patients receiving mechanical ventilation, with associated
Table 2. Indications for Bronchodilator Therapy
in Patients Receiving Mechanical Ventilation
1. Severe asthma
2. COPD
3. Acute bronchospasm or wheezing
4. Elevated airway resistance
5. Dynamic hyperinflation/intrinsic PEEP
6. Difficulty in weaning
7. Chronic ventilator-dependence
COPD, chronic obstructive pulmonary disease; PEEP, positive
end-expiratory pressure.
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Table 3. Investigations of Bronchodilator Therapy and Airway Response
in Mechanically Ventilated Patients
Author, year
(reference #) Drug (dose, mg) Aerosol device Response
Gay, 1987(76) Metaproterenol
(1.8mg)
Small-volume aerosol
generator
Increase in expiratory flow at recoil pressure of 6 cm
H2O, and reduction in peak pressure and intrinsic
PEEP
Wegener, 1987(77) Ipratropium
(0.2mg)
pMDI and adapter Decrease in inspiratory airway resistance and
significant increase in paO2
Fuller, 1990(21) Fenoterol (0.8mg)
Fenoterol
(1.75mg)
pMDI-spacer
Nebulizer
Decrease in peak airway pressure not significant with
either device
Fernandez, 1990(79) Albuterol (0.2mg)
or Ipratropium
(0.04mg)
pMDI and short
catheter
Significant decrease in peak airway pressure and
intrinsic PEEP
Bernasconi, 1990(78) Fenoterol (0.4, 0.8,
1.2mg)
Small-volume aerosol
generator and jet
nebulizer
Significant decrease in airway resistance, end-
expiratory lung volume and intrinsic PEEP
Mancebo, 1991(81) Albuterol (1.0mg) pMDI-spacer Significant decrease in airway resistance
Gay, 1991(80) Albuterol (0.3mg)
Albuterol
(2.5mg)
pMDI and adapter
Nebulizer
Similar reductions in expiratory airflow resistance with
each delivery device
Manthous , 1993(82) Albuterol (up to
10mg)
Albuterol (2.5,
5, 7.5mg)
pMDI and elbow
adapter
Nebulizer
No change in airway resistance with pMDI, significant
reduction with nebulizer
Yang, 1994(83) Ipratropium
(0.5mg)
Nebulizer Significant reduction in peak airway pressure, mean
airway pressure and mean airway resistance
Fernandez, 1994(94) Fenoterol
(0.1mg) +
Ipratropium
(0.04mg)
pMDI and short
catheter
Significant decrease in airway resistance with
combination
Dhand, 1995(26) Albuterol (1.0mg) pMDI-spacer Significant reduction of airway resistance for up to
60min
Manthous, 1993(82) Albuterol (0.5, 1.5,
3.0mg
cumulative
dose)
pMDI-spacer Significant reduction in airway resistance with 1.5 and
3.0mg albuterol
Dhand, 1996(29) Albuterol (0.4, 1.2,
2.8mg
cumulative
dose)
pMDI-spacer Significant reduction in airway resistance with 0.4, 1.2
and 2.8mg of albuterol
Mouloudi, 1998(84) Albuterol (0.6mg)
with or without
end-inspiratory
pause
pMDI-spacer Significant reduction in airway resistance. No effect of
end-inspiratory pause
Waugh, 1998(85) Albuterol (0.4,
0.8mg)
pMDI and chamber
spacers
Reduction in airway resistance with 4 puffs and 8
puffs. No difference in response between 2 chamber
spacers
Mouloudi, 1999(87) Albuterol (0.6mg) pMDI-spacer Significant reduction in airway resistance. No effect of
tidal volume 8mL/kg versus 12mL/kg body
weight
Guerin, 1999(86) Fenoterol
(0.2mg) +
Ipratropium
(0.4mg)
Fenoterol
(1.25mg) +
Ipratropium
(0.5mg)
pMDI-spacer
Nebulizer
Significant reduction in airway resistance with both
pMDI and nebulizer
Duarte, 2000(88) Albuterol (0.4,
1.0mg)
Albuterol
2.5mg
pMDI-spacer
Nebulizer
Significant reduction in airway resistance with both
pMDI and nebulizer for up to 2 h
(continued)
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FIG. 2. Left panel: effect of albuterol on maximal inspiratory resistance (Rrs max) in 12 stable mechanically ventilated
patients with COPD. Significant decreases in Rrs max occurred within 5min of administration of four puffs of albuterol. The
addition of 8 and 16 puffs (cumulative doses of 12 and 28 puffs, respectively) did not achieve a significantly greater effect
than that with 4 puffs ( p > 0.05). Right panel: the effect of four puffs of albuterol on Rrs max was confirmed in another group
of seven stable mechanically ventilated patients with COPD. Significant reduction in Rrs max with four puffs of albuterol was
sustained for 60min. Bars represent SE. **p< 0.001. (Reproduced with permission from Dhand et al.(29))
Table 3. (Continued)
Author, year
(reference #) Drug (dose, mg) Aerosol device Response
Mouloudi, 2000(89) Albuterol (0.2,
0.6mg)
pMDI-spacer Significant reduction in airway resistance. No effect of
decelerating flow pattern (pressure control) versus
square wave flow pattern (volume control)
Mouloudi, 2001(111) Albuterol (0.6mg) pMDI-spacer Significant reduction in airway resistance for up to 2 h,
but the duration of effect was variable and
unpredictable in individual patients.
Mouloudi, 2001(90) Albuterol (0.4mg) pMDI-spacer Significant reduction in airway resistance. No effect of
inspiratory flow rate (0.6 L/s versus 1.2 L/s constant
flow, volume control ventilation)
Tzoufi, 200591 Albuterol (5mg) Nebulizer Significant reduction in airway resistance. Application
of external PEEP to counterbalance intrinsic PEEP
provided additional benefits
Guerin, 2005(102) Fenoterol (10mg) Nebulizer Application of external PEEP did not provide
additional benefits in reducing airway resistance or
lung hyperinflation. External PEEP levels may need
readjustment during treatment to prevent further
hyperinflation
Malliotakis, 200792 Albuterol (0.4mg) pMDI-spacer Significant reduction in airway resistance for up to 2
hours, but there was no difference in the response
during volume control versus pressure support
ventilation with similar tidal volumes
Malliotakis, 2008(93) Salmeterol
(0.1mg)
pMDI-spacer Significant reduction in airway resistance for up to 8 h,
but the duration of effect was variable and
unpredictable in individual patients.
Kondili, 2011(109) Albuterol (0.4mg) pMDI-spacer Expiratory resistance of the respiratory system
(expiratory Rrs) was several-fold higher than
inspiratory resistance. After albuterol, there was
significant reduction in expiratory Rrs with increase
in the rate of lung emptying toward the end of
expiration. Changes in expiratory Rrs did not
correlate with changes in end-inspiratory inspiratory
resistance after albuterol
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additional costs of treatment, it is unclear if routine bron-
chodilator therapy in such a diverse group of patients con-
fers any benefit in terms of improved clinical outcomes.(106)
Assessment of the bronchodilator response
The response to bronchodilators depends on several var-
iables: patient airway geometry, degree of airway respon-
siveness, severity of disease, quantity and type of secretions,
and counter regulatory effects of airway inflammation and
other drugs. Most investigators assess response by measur-
ing inspiratory airway resistance. Airway resistance in
ventilated patients is commonly measured by performing
rapid airway occlusions at constant flow inflation.(107,108)
This technique involves performing a breath-hold at end-
inspiration by occluding the expiratory port. Total or maxi-
mal inspiratory resistance (Rrs max) can be partitioned into
minimal inspiratory resistance (Rrs min), which reflects
‘‘ohmic’’ resistance of the airways, and additional effective
resistance (D Rrs).(107,108) Similarly, airway occlusion at end-
expiration produces an increase in airway pressure to a
plateau value, signifying intrinsic positive end expiratory
pressure (PEEPi).(26) Comparisons of airway resistance and
intrinsic PEEP before and after drug administration are
useful for assessing bronchodilator response.
Most ventilated patients with COPD demonstrate a de-
crease in airway resistance and intrinsic PEEP following
bronchodilator administration (Table 3). That DRrs does
not decrease significantly after albuterol delivery with a
pMDI,(26,29) suggests that the bronchodilator effect occurs
predominantly in the central airways with little effect on
viscoelastic behavior or time-constant inhomogeneities in the
lung. Moreover, albuterol does not significantly influence the
elastic properties of the lung.(26) In contrast, a greater decline
in DRrs was noted after nebulizer delivery of albuterol and
ipratropium bromide.(86) This difference in response between
pMDIs and nebulizers could be explained by higher drug
deposition in peripheral airways with a nebulizer.
Kondilli et al.(109) measured expiratory resistance of the
respiratory system (expiratory Rrs) in mechanically venti-
lated patients with COPD exacerbations. They found that
albuterol significantly reduced expiratory Rrs, and enhanced
the rate of lung emptying toward to the end of expiration.
Interestingly, these investigators did not find any correlation
between changes in expiratory Rrs and changes in end-
inspiratory resistance following albuterol administration.
This discrepancy could be attributed to additional contribu-
tions by flow limitation and airway narrowing during expi-
ration to the total expiratory resistance.
In bench models, drug delivery was increased during
simulated spontaneous breaths compared to controlled me-
chanical breaths.(5) However, in ventilated patients with
acute exacerbations of COPD, the bronchodilator response
did not differ between controlled mechanical ventilation and
inspiratory pressure support ventilation.(92) The use of pro-
pofol for sedation was a significant confounder of that
study,(92) because its bronchodilator effect(110) may have
influenced the response to albuterol during controlled me-
chanical ventilation.
Drug toxicity
Administration of high doses of b-adrenergic bronchodi-
lators causes tachycardia, and has the potential to cause at-
rial and ventricular arrhythmias.(82) In the recent ARDS
Network study regular administration of nebulized albuterol
produced a significant but modest increase in heart rate but
did not result in an increased incidence of atrial fibrillation or
ventricular arrhythmias.(106)
Techniques of Administration
The optimal techniques for administration of inhaled
drugs to ventilated patients are based on the various factors
discussed above. The technique employed may have to
compromise between the optimum operating characteristics
of the device and the patient’s condition. For example, a
higher duty cycle increases aerosol delivery,(5,67) but it may
worsen dynamic hyperinflation in patients with airflow
Table 4. Optimal Technique for Drug Delivery
by pMDI in Ventilated Patients
1. Review order, identify patient, and assess need for
bronchodilator.
2. Assess airway, remove excess secretions.
3. Shake pMDI and warm to hand temperature (prime if not
used within 24 h).
4. Place pMDI in adapter in ventilator circuit.
5. Remove HME. Do not disconnect humidifier.
6. Coordinate pMDI actuation with beginning of
inspiration.
7. Wait at least 15 s between actuations; administer total
dose.
8. Monitor for adverse response.
9. Reconnect HME.
10. Document clinical outcome.
pMDI, metered-dose inhaler; HME, heat and moisture exchanger.
Table 5. Optimal Technique for Drug Delivery
by Jet Nebulizer in Ventilated Patients
1. Review order, identify patient, and assess need for
bronchodilator.
2. Assess airway, remove excess secretions if present.
3. Place drug in nebulizer, do not exceed manufacturer
recommendations
4. Place nebulizer in the inspiratory line 18 in (46m) from
the patient wye connector or proximal to the ventilator.
5. Use minimal flow-by or continuous flow during
nebulizer operation.
6. Remove HME from circuit (do not disconnect humidifier).
7. Set gas flow to nebulizer at 2–10 L/min, based on
manufacturer label.
a. Use ventilator to power nebulizer if it meets the
nebulizer flow requirements and cycles on inspiration, or
b. Use continuous flow from external source (*50 psi).
8. Adjust ventilator volume or pressure limit and alarms to
compensate for added flow.
9. Run until nebulizer begins to sputter.
10. Remove nebulizer from circuit, rinse with sterile water
and run dry, store in safe place.
11. Reconnect humidifier or HME, return ventilator settings
and alarms to previous values.
12. Monitor patient for adverse response.
13. Assess outcome and document findings.
HME, heat and moisture exchanger.
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limitation.(72) With this caveat in mind, the technique of ad-
ministration for pMDIs in ventilated patients is shown in
Table 4 and that for nebulizers in Table 5. The key aspects of
the technique with pMDIs are to place an appropriate
adapter at a short distance (*15 cm) from the endotracheal
tube and to synchronize actuation with inspiratory flow. For
nebulizers, it is critical to use the device as recommended by
the manufacturer and to place it at a distance from the pa-
tient. When these techniques are employed, adequate pul-
monary drug deposition is achieved(5,6,63) and a significant
bronchodilator response is observed (Table 3). However,
most mechanically ventilated patients do not show incre-
mental effects with higher drug doses of bronchodilators.(29)
Other classes of inhaled drugs may demonstrate linear
dose–response relationships.
In summary, aerosol delivery in mechanically ventilated
patients is complex. When meticulous attention is paid to the
specific variables described above, it is possible to provide
effective, reliable, consistent, and precise delivery of aerosols
to the lungs of mechanically ventilated patients. When these
factors are not carefully controlled and the optimum tech-
nique is not utilized, a greater proportion of the aerosol de-
posits in the ventilator circuit or artificial airways resulting in
reduced efficiency of pulmonary drug delivery and the po-
tential for ineffective therapy.
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